ChromaDex Announces Two Patent Issuances for Novel
Post# of 297
Posted On: 11/28/2014 5:57:54 PM
ChromaDex Announces Two Patent Issuances for Novel Ingredient, Pterostilbene
| Monday, November 24, 2014 7:25 AM |
[PR Newswire] - IRVINE, Calif., Nov. 24, 2014 /PRNewswire/ -- The U.S. Patent and Trademark Office has granted patent #8,809,400 B2 (referred to as the '400 patent) and #8,841,350 B2 (referred to as the '350 patent) pertaining to the ingredient pterostilbene, both of which are licensed exclusively to ChromaDex Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. These are the second and third ChromaDex-held patents issued for pterostilbene and several additional patents are pending. The '400 patent, entitled "Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration," relates to a method of using pterostilbene to forestall, prevent and reverse the effects of neuronal and behavioral aging and the development of neurodegenerative diseases. Specifically, pterostilbene is shown in research studies to be effective in reversing motor deficits and working memory of subjects.
http://us.rd.yahoo.com/finance/news/rss/story...00518.html
~ This Week's OTC News In Review! ~
Covering the entire market and teaching traders! Visit here to learn technicals and fundamentals >>
http://www.stockgoodies.com/lessons.html
~ http://www.fallenheroesfund.org/ ~
St. Jude 2014 Drive has started >> http://tinyurl.com/St-Jude-2014
| Monday, November 24, 2014 7:25 AM |
[PR Newswire] - IRVINE, Calif., Nov. 24, 2014 /PRNewswire/ -- The U.S. Patent and Trademark Office has granted patent #8,809,400 B2 (referred to as the '400 patent) and #8,841,350 B2 (referred to as the '350 patent) pertaining to the ingredient pterostilbene, both of which are licensed exclusively to ChromaDex Corp. (OTCQX: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. These are the second and third ChromaDex-held patents issued for pterostilbene and several additional patents are pending. The '400 patent, entitled "Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration," relates to a method of using pterostilbene to forestall, prevent and reverse the effects of neuronal and behavioral aging and the development of neurodegenerative diseases. Specifically, pterostilbene is shown in research studies to be effective in reversing motor deficits and working memory of subjects.
http://us.rd.yahoo.com/finance/news/rss/story...00518.html
~ This Week's OTC News In Review! ~
Covering the entire market and teaching traders! Visit here to learn technicals and fundamentals >>
http://www.stockgoodies.com/lessons.html
~ http://www.fallenheroesfund.org/ ~
St. Jude 2014 Drive has started >> http://tinyurl.com/St-Jude-2014
(0)
(0)Scroll down for more posts ▼